A study titled “Cytokines Removal During Ex-Vivo Lung Perfusion: Initial Clinical Experience”, by researchers Boffini et al. was published in August 2023 in Transplant International. Covering a period of 10 years, from 2011 to 2020, research by has demonstrated for the first time – on an unparalleled large case series of 54 lung treatments intended for transplantation – that the removal of cytokines during Ex-Vivo Lung Perfusion1 (EVLP) § allows for a significant increase in the number of transplantable organs, reducing postoperative complications and significantly improving survival:100% of patients who received an organ treated with cytokine adsorption were alive one year after transplantation, compared to 64% of the group not treated with adsorption.
Read more at this link
Boffini M, Marro M, Simonato E, Scalini F, Costamagna A, Fanelli V, Barbero C, Solidoro P, Brazzi L, Rinaldi M. Cytokines Removal During Ex-Vivo Lung Perfusion: Initial Clinical Experience. Transpl Int. 2023 Aug 14;36:10777. doi: 10.3389/ti.2023.10777. PMID: 37645241; PMCID: PMC10460908.
§ Ex vivo lung perfusion (EVLP) is an innovative therapy applied to donor lungs outside of the body before transplantation that improves organ quality and makes lungs that were previously unsuitable safe for transplant.